In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Array paying next to nothing for Novartis BRAF inhibitor

This article was originally published in Scrip

Executive Summary

As its acquisition of GlaxoSmithKline's oncology portfolio draws nearer to closing, Novartis is essentially paying Array BioPharma to take over development and commercialization of the BRAF inhibitor encorafenib (LGX818) just one month after the Swiss big pharma gave back its rights to Array's MEK inhibitor binimetinib under attractive terms.

You may also be interested in...



Array Raring To Go Commercially With First Approval – Mektovi/Braftovi

Array believes that a zero copay offer for patients will help its newly FDA-approved Mektovi/Braftovi combination stand out from the crowd in melanoma and notes that the regimen also has potential in a larger indication – colon cancer.

Array Rises As COLUMBUS Clears Phase III Melanoma Hurdle

Shares in Array Biopharma shot up by more than 80% on the release of top-line Phase III data from its COLUMBUS study of encorafenib and binimetinib, but more details are needed to gauge how the combination may fare against Novartis and Roche’s more established combos, and the newer IO therapies.

Finance Watch: Up, Up And Away – Biopharma Stocks Keep Rising

Public Company Edition: Drug developers continue to take advantage of investors’ preference for biotechnology investments, with CRISPR, Acceleron and BioNTech raising massive sums. The wealth isn’t spreading to everyone, however, as DBV Technologies is restructuring and cutting jobs. 

Topics

Related Companies

UsernamePublicRestriction

Register

WI964931

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel